Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.20M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 2.69M

Average 1.44M

CATX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Perspective Therapeutics, Inc.AMEX: CATX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -1381.6%

Gross margin was -1381.6% in Q1 FY2026, down 1267.5 pp from a year earlier. On a trailing-twelve-month basis it was -489.8%, down 407.5 pp year over year. Over 3 fiscal years it narrowed by 290.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-1381.6%+869.6 pp QoQ
Last fiscal yearDec 2025
-267.8%-209.2 pp YoY
LTMMar 2026
-489.8%-407.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1267.5 pp——
1 year-209.2 pp——
3 years-290.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-267.8%
Year-over-year change
-209.2pp

Gross Margin vs competitors

How CATX compares with its peers on the latest reported figures

  • CATX's LTM Mar 2026 gross margin of -489.8% is the lowest of the 5 companies compared; the peer median is 80.1%.
  • Its year-over-year change of -407.5 pp is the lowest of 5, against a peer median of -1.2 pp.
  • Over three fiscal years its change of -290.8 pp compares with a peer median of -0.7 pp.
CATX Competitors Peer median
Gross Margin for CATX and competitors
Company Period LTM level YoY 3-year change
DCTHDelcath Systems, Inc.LTM Mar 202686.0% +1.1 pp+11.4 pp
TLSITriSalus Life Sciences, Inc.LTM Mar 202685.1% -0.5 pp+2.8 pp
NVCRNovoCure LimitedLTM Mar 202675.2% -2.0 pp-4.1 pp
SRTSSensus Healthcare, Inc.LTM Mar 202637.7% -18.3 pp-23.4 pp
CATXPerspective Therapeutics, Inc.LTM Mar 2026-489.8% -407.5 pp-290.8 pp
Peer median (excluding CATX) 80.1%-1.2 pp-0.7 pp

Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.8M7.1M1.43M1.45M884K
Cost of Revenue6.18M5.47M000
Gross Profit4.62M1.63M1.43M(852K)(2.37M)
Gross Margin42.8%23.0%100.0%-58.6%-267.8%
Research & Development2.58M2.6M21.31M41.64M84.22M
Selling, General & Admin9.43M14.21M21.06M26.61M30.23M
Operating Expenses12.01M17.43M42.38M92.34M113.56M
Depreciation & Amortization248K344K981K2.31M3.25M
EBITDA(7.39M)(14.84M)(39.96M)10.46M(100.8M)
EBITDA Margin-68.5%-208.9%-2786.6%719.3%-11402.8%
Operating Income(7.39M)(15.18M)(40.94M)10.46M(113.56M)
Operating Margin-68.5%-213.7%-2855.0%719.3%-12846.6%
Interest Income119K1.12M934K10.52M8.11M
Interest Expense119K084K(48K)376K
Other Income / Expenses119K512K835K(91.84M)9.14M
Income Before Tax(7.27M)(14.67M)(40.11M)(81.38M)(104.43M)
Pre-Tax Margin-67.4%-206.5%-2796.8%-5596.7%-11813.1%
Income Tax Expense(119K)0(2.65M)(2.1M)(793K)
Net Income(7.15M)(14.67M)(46.51M)(79.28M)(103.12M)
Net Margin-66.3%-206.5%-3243.2%-5452.5%-11665.3%
EPS (Basic)(0.13)(0.27)(0.85)(1.23)(1.40)
EPS (Diluted)(0.13)(0.27)(0.85)(1.23)(1.40)
Weighted Avg Shares54.91M54.91M54.91M64.43M73.81M
Weighted Avg Shares (Diluted)54.91M54.91M54.91M64.43M73.81M

Perspective Therapeutics, Inc.

AMEX:CATX

Intrinsic Alpha fair value

Locked

Current Price

$0.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.